5:13 PM
 | 
Mar 27, 2013
 |  BC Extra  |  Company News

Aastrom terminates CLI program, halving staff

Aastrom Biosciences Inc. (NASDAQ:ASTM) fell $0.44 (38%) to $0.71 on Wednesday after announcing that it will no longer develop its only product, ixmyelocel-T, to treat critical limb ischemia (CLI) and will instead focus R&D resources on developing the product...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >